Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), retaining the ...

Actinium Pharmaceuticals is a fantastic biotech company with a promising solution for a subset of AML patients. See why ATNM ...

(RTTNews) - Actinium Pharmaceuticals Inc. (ATNM) said that median overall survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Actinium Pharma – Pivotal Results From Key New Drug In The Fight Against Cancer Sandesh Seth, CEO & Chairman of the Board of Actinium Pharmaceuticals (NASDAQ: ATNM), was recently a guest on ...

Actinium Pharmaceuticals (NYSEMKT:ATNM) just reported results for the first quarter of 2024. Actinium Pharmaceuticals reported earnings per share of -31 cents. This was above the analyst estimate for ...

NYSEAM:ATNM) Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity ...

NEW YORK - Actinium Pharmaceuticals (NYSE:ATNM), Inc. (NYSE AMERICAN: ATNM), a biotechnology firm specializing in targeted radiotherapies, has announced significant results from its Phase 3 SIERRA ...

(RTTNews) - Actinium Pharmaceuticals Inc. (ATNM) said that median overall survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow ...

Invest with your heart and your phone with as little as $1 with these ESG and socially responsible investing apps.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...